We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-29.17%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$186M
AUM Growth
+$106M
Cap. Flow
+$5.12M
Cap. Flow %
2.76%
Top 10 Hldgs %
78.1%
Holding
120
New
32
Increased
25
Reduced
31
Closed
26

Top Buys

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$5.9M
2
HIND
Vyome Holdings
HIND
+$3.25M
3
CRMD icon
CorMedix
CRMD
+$2.09M
4
TRAW icon
Traws Pharma
TRAW
+$1.84M
5
XBIO icon
Xenetic Biosciences
XBIO
+$1.45M

Top Sells

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$2.04M
2
SHIPW
Seanergy Maritime Holdings Corp Class A Warrants
SHIPW
+$1.54M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$1.35M
4
BCLI
BRAINSTORM CELL THERAPUTC
BCLI
+$622K
5
CANF
Can-Fite BioPharma American Depositary Shares
CANF
+$610K

Sector Composition

Rank Sector Weight
1 Healthcare 14.92%
2 Technology 1.81%
3 Industrials 0.77%
4 Consumer Discretionary 0.32%
5 Real Estate 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVO icon
26
CervoMed
CRVO
$23.7M
$865K 0.47%
6,238
-10
-0.2% -$1.61K
BHVN
27
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$828K 0.45%
+19,850
New +$839K
CVM.WS
28
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$764K 0.41%
855
-537
-39% -$480K
TRAW icon
29
Traws Pharma
TRAW
$7.81M
$682K 0.37%
+2,141
New +$1.84M
CTXR icon
30
Citius Pharmaceuticals
CTXR
$13.7M
$640K 0.34%
+33,817
New +$892K
ORMP icon
31
Oramed Pharmaceuticals
ORMP
$171M
$593K 0.32%
185,800
-168,913
-48% -$563K
SOLO
32
DELISTED
Electrameccanica Vehicles Corp. Ltd.
SOLO
$587K 0.32%
288,408
-164,388
-36% -$412K
SHIP icon
33
Seanergy Maritime Holdings
SHIP
$348M
$583K 0.31%
7,563
-2,874
-28% -$267K
TOPS icon
34
TOP Ships
TOPS
$4.11M
$572K 0.31%
+34
New +$1.43M
HURA
35
TuHURA Biosciences
HURA
$136M
$526K 0.28%
+544
New +$1.02M
PHAS
36
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$520K 0.28%
124,788
+41,857
+50% +$334K
AVEO
37
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$498K 0.27%
590
+69
+13% +$513
XBIO icon
38
Xenetic Biosciences
XBIO
$5.73M
$484K 0.26%
+40,455
New +$1.45M
AMRN
39
Amarin Corp
AMRN
$293M
$470K 0.25%
1,550
-22
-1% -$7.68K
GNPX icon
40
Genprex
GNPX
$4.05M
$462K 0.25%
13
-2
-13% -$84.5K
CYTO
41
DELISTED
Altamira Therapeutics Ltd
CYTO
$461K 0.25%
419
+110
+36% +$122K
SEEL
42
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$451K 0.24%
+128
New +$771K
MBOT icon
43
Microbot Medical
MBOT
$113M
$442K 0.24%
83,333
– –
VXRT
44
DELISTED
Vaxart
VXRT
$430K 0.23%
1,197,710
+277,063
+30% +$181K
GNCA
45
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
$429K 0.23%
+1,481
New +$5.06K
VBIV
46
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$413K 0.22%
+29,205
New +$612K
NSPR icon
47
InspireMD
NSPR
$32.1M
$408K 0.22%
20,905
+19,918
+2,018% +$805K
ADXS
48
DELISTED
Advaxis Inc
ADXS
$403K 0.22%
1,521,982
+1,480,260
+3,548% +$1.01M
PSTV icon
49
Plus Therapeutics
PSTV
$25.9M
$389K 0.21%
+303
New +$1.09M
TOVX icon
50
Theriva Biologics
TOVX
$9.8M
$379K 0.2%
3,342
-273
-8% -$33K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2019 Portfolio in Review

As of Q3 2019, Sabby Management held 120 positions worth $186M, up 133% from $79.5M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Sabby Management's Q3 2019 filing shows 32 new, 25 increased, 31 reduced and 26 closed positions. Its largest new stake was Pareteum Corporation: 2,248,578 shares worth $2.9M. The largest sale was Ampio Pharmaceuticals Inc., an estimated $2.04M.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 37% a quarter earlier, followed by Technology and Industrials.

  • Sabby Management's largest Q3 2019 buy was Pareteum Corporation: 2,248,578 shares worth $2.9M.
  • Sabby Management added most to Advaxis Inc in Q3 2019, an estimated $1.01M increase.
  • Sabby Management's biggest Q3 2019 reduction was Odonate Therapeutics, Inc. Common Stock, cutting an estimated $1.35M.
  • Sabby Management fully exited Ampio Pharmaceuticals Inc. in Q3 2019, selling an estimated $2.04M.
  • Sabby Management's ten largest holdings make up 78% of its $186M portfolio in Q3 2019.
  • Sabby Management opened 32 new positions and closed 26 in Q3 2019.
  • Sabby Management's portfolio value rose 133% quarter-over-quarter to $186M.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.